NVMDF - NVMDF STOCK NEWS

Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) has completed the sale of its investment in the Synthesis Institute for €1,200,000, realizing a 60% return on investment. This transaction generated approximately CAN$1,760,000 in gross proceeds, enhancing Novamind's cash position to CAN$9,207,945 without any debt. The company has chosen not to invest in the Circadia Center to focus on expanding its clinic network and clinical research in the U.S. Novamind aims to leverage its scalable business model for further growth and upcoming clinical trials.

Novamind Inc. announced the opening of its new clinic in Draper, Utah, specializing in integrative psychiatric care for treatment-resistant conditions like depression and PTSD. This clinic marks the fifth location and is part of an expansion plan to open four new clinics by September 2021. The facility will incorporate psychedelic-assisted psychotherapy and serve as a research site for clinical trials. CEO Yaron Conforti emphasized the importance of expanding access to various treatments in response to high patient demand, aiming to innovate mental health care.

Novamind Inc. has announced its application for trading on the OTCQB Venture Market, aiming to enhance visibility and accessibility for U.S. investors. The application for DTC eligibility will simplify trading processes for its common shares, which currently trade on the CSE and FSE. CEO Yaron Conforti highlighted this move as a significant milestone in attracting U.S. investment in Novamind's mental health initiatives, particularly in psychedelic medicine. Approval from the OTC Markets Group is required for the trading to commence.

Novamind Inc. has announced that its subsidiary, Cedar Clinical Research, will host a Phase IIb clinical trial for Bionomics Limited's BNC210, aimed at treating post-traumatic stress disorder (PTSD). This study will compare BNC210's effectiveness against a placebo in adults with PTSD, a condition affecting 8.3% of American adults. Having received Fast Track Designation from the FDA, BNC210 is seen as a new, potentially effective option for PTSD treatment. CCR is currently involved in nine other trials, highlighting its expertise in mental health research.

Novamind (CSE:NM)(OTC PINK:NVMDF) has launched the Psychedelic Therapy Frontiers podcast aimed at psychedelic medicine researchers and clinicians. Hosted by Dr. Stephen Thayer and Dr. Reid Robison, the podcast features discussions on psychedelic-assisted psychotherapy, harm reduction, and equitable access to care. This initiative responds to the growing interest in psychedelic therapies among mental health professionals. Novamind aims to enhance treatment access for conditions like depression and anxiety through its education division, leveraging innovative therapy protocols.

Novamind Inc. has appointed Dr. Paul Thielking as Chief Scientific Officer, who will lead its clinical research arm focused on psychedelic medicine. Dr. Thielking's responsibilities include overseeing investigator-led studies and developing treatment protocols for conditions like cancer-related depression. His previous experience includes integrating ketamine-assisted psychotherapy at the Huntsman Cancer Institute. Novamind aims to address urgent mental health needs through innovative treatments, emphasizing the significance of psychedelic therapy in tackling mental health issues.

Novamind Inc. has announced a US$1,000,000 strategic investment in a stealth-mode drug development company focused on neuropsychiatric disorders. This minority equity investment is part of a larger Series A financing round that raised US$25,000,000 in total. The investment aims to leverage Novamind's expertise in patient recruitment for developing innovative treatments. Further details will be shared as confidentiality restrictions are lifted. Novamind provides access to psychedelic medicine through clinics and research facilities.

Novamind announced its participation in the H.C. Wainwright Psychedelics in Psychiatry Conference on June 17, 2021. CEO Yaron Conforti will present the company's strategy to enhance access to psychedelic medicine through its specialized psychiatry clinics. The presentation will be available for on-demand viewing. Conforti and Chief Medical Officer Dr. Reid Robison will participate in panels discussing the revolutionary impact of psychedelics in psychiatry. Novamind's expertise includes innovative treatment protocols and partnerships with leading pharmaceutical firms.

Novamind Inc. and the Wholeness Center are launching a new clinical offering called Frontline Ketamine-Assisted Psychotherapy (KAP) in Utah and Colorado. This initiative is designed to address the mental health needs of frontline healthcare workers exposed to COVID-19-related stress and trauma. The program will initially enroll 40 participants, with treatments commencing in late June 2021. Co-developed by experts in psychedelic medicine, this protocol aims to significantly reduce burnout and isolation reported by healthcare professionals. Both organizations leverage extensive experience in psychedelic therapy.